|
Gene: PXN |
Gene summary for PXN |
Gene summary. |
Gene information | Species | Human | Gene symbol | PXN | Gene ID | 5829 |
Gene name | paxillin | |
Gene Alias | PXN | |
Cytomap | 12q24.23 | |
Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | A0A140VJQ8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5829 | PXN | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.83e-03 | 3.82e-01 | -0.1808 |
5829 | PXN | HTA11_78_2000001011 | Human | Colorectum | AD | 3.93e-03 | 3.77e-01 | -0.1088 |
5829 | PXN | HTA11_347_2000001011 | Human | Colorectum | AD | 3.51e-14 | 5.84e-01 | -0.1954 |
5829 | PXN | HTA11_696_2000001011 | Human | Colorectum | AD | 7.69e-04 | 3.13e-01 | -0.1464 |
5829 | PXN | HTA11_866_2000001011 | Human | Colorectum | AD | 1.05e-02 | 2.92e-01 | -0.1001 |
5829 | PXN | A015-C-203 | Human | Colorectum | FAP | 4.49e-04 | -9.19e-02 | -0.1294 |
5829 | PXN | A002-C-205 | Human | Colorectum | FAP | 2.26e-05 | -2.33e-01 | -0.1236 |
5829 | PXN | A015-C-104 | Human | Colorectum | FAP | 4.73e-06 | -1.07e-01 | -0.1899 |
5829 | PXN | A002-C-016 | Human | Colorectum | FAP | 8.81e-06 | -1.80e-01 | 0.0521 |
5829 | PXN | A002-C-116 | Human | Colorectum | FAP | 3.78e-11 | -2.04e-01 | -0.0452 |
5829 | PXN | F034 | Human | Colorectum | FAP | 2.87e-05 | -1.85e-01 | -0.0665 |
5829 | PXN | F072B | Human | Colorectum | FAP | 2.94e-03 | -1.77e-01 | 0.257 |
5829 | PXN | LZE4T | Human | Esophagus | ESCC | 4.28e-08 | -1.01e-01 | 0.0811 |
5829 | PXN | LZE7T | Human | Esophagus | ESCC | 2.23e-04 | -9.42e-03 | 0.0667 |
5829 | PXN | LZE8T | Human | Esophagus | ESCC | 8.23e-05 | 2.36e-02 | 0.067 |
5829 | PXN | LZE20T | Human | Esophagus | ESCC | 4.81e-04 | -8.51e-02 | 0.0662 |
5829 | PXN | LZE22D1 | Human | Esophagus | HGIN | 6.59e-03 | -9.25e-02 | 0.0595 |
5829 | PXN | LZE24T | Human | Esophagus | ESCC | 9.31e-10 | 1.76e-02 | 0.0596 |
5829 | PXN | LZE6T | Human | Esophagus | ESCC | 3.02e-02 | 1.31e-01 | 0.0845 |
5829 | PXN | P2T-E | Human | Esophagus | ESCC | 1.24e-25 | 5.04e-01 | 0.1177 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:1902905110 | Oral cavity | LP | positive regulation of supramolecular fiber organization | 81/4623 | 209/18723 | 4.30e-06 | 8.80e-05 | 81 |
GO:1902903110 | Oral cavity | LP | regulation of supramolecular fiber organization | 131/4623 | 383/18723 | 1.58e-05 | 2.78e-04 | 131 |
GO:0034614110 | Oral cavity | LP | cellular response to reactive oxygen species | 61/4623 | 155/18723 | 3.66e-05 | 5.43e-04 | 61 |
GO:0043434110 | Oral cavity | LP | response to peptide hormone | 138/4623 | 414/18723 | 4.00e-05 | 5.87e-04 | 138 |
GO:0032970110 | Oral cavity | LP | regulation of actin filament-based process | 133/4623 | 397/18723 | 4.21e-05 | 6.09e-04 | 133 |
GO:190165317 | Oral cavity | LP | cellular response to peptide | 122/4623 | 359/18723 | 4.22e-05 | 6.10e-04 | 122 |
GO:005149519 | Oral cavity | LP | positive regulation of cytoskeleton organization | 82/4623 | 226/18723 | 6.26e-05 | 8.46e-04 | 82 |
GO:0032956110 | Oral cavity | LP | regulation of actin cytoskeleton organization | 120/4623 | 358/18723 | 9.47e-05 | 1.18e-03 | 120 |
GO:0007015110 | Oral cavity | LP | actin filament organization | 143/4623 | 442/18723 | 1.44e-04 | 1.65e-03 | 143 |
GO:0110053110 | Oral cavity | LP | regulation of actin filament organization | 92/4623 | 278/18723 | 9.25e-04 | 7.85e-03 | 92 |
GO:007137515 | Oral cavity | LP | cellular response to peptide hormone stimulus | 95/4623 | 290/18723 | 1.12e-03 | 9.19e-03 | 95 |
GO:003158918 | Oral cavity | LP | cell-substrate adhesion | 111/4623 | 363/18723 | 5.94e-03 | 3.53e-02 | 111 |
GO:0051017110 | Oral cavity | LP | actin filament bundle assembly | 53/4623 | 157/18723 | 6.54e-03 | 3.83e-02 | 53 |
GO:003444619 | Oral cavity | LP | substrate adhesion-dependent cell spreading | 38/4623 | 108/18723 | 9.38e-03 | 4.99e-02 | 38 |
GO:000697929 | Skin | cSCC | response to oxidative stress | 184/4864 | 446/18723 | 8.57e-13 | 4.89e-11 | 184 |
GO:006219729 | Skin | cSCC | cellular response to chemical stress | 138/4864 | 337/18723 | 1.10e-09 | 4.23e-08 | 138 |
GO:000030228 | Skin | cSCC | response to reactive oxygen species | 97/4864 | 222/18723 | 6.88e-09 | 2.25e-07 | 97 |
GO:003459928 | Skin | cSCC | cellular response to oxidative stress | 117/4864 | 288/18723 | 3.37e-08 | 8.95e-07 | 117 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa04670 | Colorectum | AD | Leukocyte transendothelial migration | 41/2092 | 114/8465 | 4.60e-03 | 2.20e-02 | 1.40e-02 | 41 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa051001 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051631 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa045101 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa046701 | Colorectum | AD | Leukocyte transendothelial migration | 41/2092 | 114/8465 | 4.60e-03 | 2.20e-02 | 1.40e-02 | 41 |
hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa051002 | Colorectum | SER | Bacterial invasion of epithelial cells | 36/1580 | 77/8465 | 1.56e-08 | 3.45e-07 | 2.50e-07 | 36 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PXN | insertion | Nonsense_Mutation | novel | c.1223_1224insTGTGTGAGAACTAAATGAGATAATGC | p.Asn409ValfsTer2 | p.N409Vfs*2 | P49023 | protein_coding | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PXN | SNV | Missense_Mutation | rs201427575 | c.1127N>G | p.Lys376Arg | p.K376R | P49023 | protein_coding | tolerated(0.07) | benign(0.022) | TCGA-EA-A3HR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PXN | SNV | Missense_Mutation | novel | c.1346N>T | p.Thr449Met | p.T449M | P49023 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PXN | SNV | Missense_Mutation | novel | c.1185C>G | p.His395Gln | p.H395Q | P49023 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PXN | SNV | Missense_Mutation | c.1067A>G | p.Gln356Arg | p.Q356R | P49023 | protein_coding | deleterious(0.02) | probably_damaging(0.948) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PXN | SNV | Missense_Mutation | c.742N>A | p.Val248Ile | p.V248I | P49023 | protein_coding | tolerated(0.35) | benign(0.236) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
PXN | SNV | Missense_Mutation | rs766354430 | c.1189N>A | p.Val397Ile | p.V397I | P49023 | protein_coding | tolerated(0.07) | benign(0.428) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PXN | SNV | Missense_Mutation | c.1618C>T | p.His540Tyr | p.H540Y | P49023 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PXN | SNV | Missense_Mutation | c.1602N>T | p.Gln534His | p.Q534H | P49023 | protein_coding | deleterious(0.02) | benign(0.236) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PXN | SNV | Missense_Mutation | rs748821995 | c.16N>A | p.Ala6Thr | p.A6T | P49023 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5829 | PXN | NA | H2O2 | 9590268 | ||
5829 | PXN | NA | 1,2,4,5-BENZENETETRAAMINE TETRAHYDROCHLORIDE | CHEMBL456559 | 18989950 | |
5829 | PXN | NA | ANTISENSE OLIGONUCLEOTIDES | 14576084 | ||
5829 | PXN | NA | LOVASTATIN | LOVASTATIN | 11581207 |
Page: 1 |